



## Press release

### **TxCell to publish 2015 annual results and update its strategy and perspectives on Thursday, March 10, 2016**

**Valbonne, France, March 7, 2016 – TxCell SA (FR0010127662 – TXCL)**, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, will release on Thursday, March 10, after market closes, its consolidated financial results for the year ended December 31, 2015 and update its strategy and perspectives.

A conference call and webcast will be held on Friday, March 11, at 3:30pm (CET) in English. The conference call will be followed by a Q&A session.

Investors and analysts wishing to participate can access the call via the following teleconferencing number: +33 (0)1 70 77 09 44

The webcast can be followed live online via the link:

<http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135299977&PIN=73954371>

Following the live call, a replay will be available for 90 days. To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 299977#

**About TxCell:** [www.txcell.com](http://www.txcell.com)

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell's lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, should enter clinical trials in 2016. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees.

#### **Contacts:**

##### **TxCell**

BD & Communication Department  
Tel: +33(0) 4 97 21 83 00  
Fax: +33(0) 4 93 64 15 80  
[contact@txcell.com](mailto:contact@txcell.com)

##### **Image Box – Press relations**

Neil Hunter / Michelle Boxall  
Tel: +44(0) 20 8943 4685  
[neil.hunter@imageboxpr.co.uk](mailto:neil.hunter@imageboxpr.co.uk)  
[michelle.boxall@imageboxpr.co.uk](mailto:michelle.boxall@imageboxpr.co.uk)

##### **NewCap – Investor relations**

Julien Perez / Pierre Laurent  
Tel: +33 (0)1 44 71 98 52  
[txcell@newcap.eu](mailto:txcell@newcap.eu)

**Disclaimer:**

This press release contains certain forward-looking statements concerning TxCell and its business. Such forward-looking statements are based on assumptions that TxCell considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of TxCell registered by the French Financial Markets Authority (Autorité des marchés financiers) on June 11, 2015 under number R. 15-049, and in the update of the registration document filed with the AMF on January 25, 2016 under number D.15-0402-A01, available on the Company's website ([www.txcell.com](http://www.txcell.com)) and to the development of economic conditions, financial markets and the markets in which TxCell operates. The forward-looking statements contained in this press release are also subject to risks not yet known to TxCell or not currently considered material by TxCell. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of TxCell to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, TxCell shares in any country.